Shaji Kumar on the Changing Immunotherapy Landscape in Myeloma

By DocWire News Editors - Last Updated: April 27, 2023

Shaji Kumar, MD, a myeloma specialist from Mayo Clinic in Rochester, Minnesota, discusses the upcoming changes in the immunotherapy landscape for multiple myeloma, following the approval of chimeric antigen receptor (CAR) T-cell therapies and the introduction of B-cell maturation antigen-targeting agents.

Post Tags:Multiple Myeloma Oncology Videos

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Jordana JampelMelanoma | April 28, 2025

Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation.

The Role of Multidisciplinary Care in Head and Neck Cancer

Eric Bergson, MDHead and Neck Cancer | April 24, 2025

Dr. Eric Dr. Bergson about the importance of head and neck cancer awareness, how to integrate screening into routine care.

AI Assessment of Tongue Muscle Composition and Risk for Dysphagia in Head and Neck Cancers

Jordana JampelHead and Neck Cancer | March 28, 2025

AI analysis provides an opportunity for timely intervention to improve the ability to swallow as well as quality of life.

Cactus Leaf Compounds Provide Positive Potential in Treatment of Epstein-Barr Virus–Positive Head and Neck Cancers

Jordana JampelHead and Neck Cancer | March 26, 2025

Euphorbis tirucalli leaf extract has the potential ability to inhibit EBV-positive cell proliferation.

A Novel Immunotherapy Strategy May Improve Melanoma Treatment

Rob DillardMelanoma | March 20, 2025

A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as MARCO.

Shaji Kumar on the Changing Immunotherapy Landscape in Myeloma

Related Posts